Loading clinical trials...
Loading clinical trials...
A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
Conditions
Interventions
Human T Lymphoid Progenitor (HTLP) injection
Locations
1
France
Unité d'Immunologie Hématologie Rhumatologie Pédiatrique (UIHR),
Paris, Île-de-France Region, France
Start Date
May 13, 2020
Primary Completion Date
September 3, 2023
Completion Date
June 3, 2025
Last Updated
September 27, 2022
NCT07408037
NCT07360977
NCT01696721
NCT06984276
NCT06899009
NCT07315711
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions